The strongest European healthtech companies will not only prove that their product works.

They will prove that the company can move.

They will know which markets matter first, which proof needs to be built, which buyers have budget, which partnerships unlock access, and which expansion path is actually credible.

That is the difference between a promising company and a venture scale company.

New HealthVC newsletter:

Europe’s Healthtech Distribution Problem